Updated:
Institute for Follicular Lymphoma Innovation
The Institute for Follicular Lymphoma Innovation was established as a nonprofit entity to consolidate and direct research funding specifically toward...
Institute for Follicular Lymphoma Innovation
The Institute for Follicular Lymphoma Innovation was established as a nonprofit entity to consolidate and direct research funding specifically toward follicular lymphoma, a blood cancer affecting roughly 200,000 patients globally. While many cancer foundations spread resources across multiple indications, this organization's formation reflects a focused response to a treatment landscape where the disease remains incurable with standard approaches. The institute funds investigator-initiated research, biomarker discovery, and novel immunotherapeutic strategies through an annual grant cycle, with award decisions guided by a scientific advisory board of lymphoma specialists. Its Diamond Bar, California base serves as an administrative hub rather than a clinical site, keeping operational overhead low to maximize capital deployment into peer-reviewed science. The foundation's grantmaking prioritizes high-risk, high-reward projects unlikely to attract immediate commercial investment. Published award portfolios have supported work on bispecific antibodies, CAR-T cell therapy optimization, and epigenetic modifying agents — mechanisms that have shown promise in relapsed follicular lymphoma but require dedicated funding to reach proof-of-concept. The institute allocates across academic medical centers in North America and Europe, with named grantees historically including researchers at institutions such as MD Anderson Cancer Center and Memorial Sloan Kettering. It does not operate its own laboratory or clinical network, functioning instead as a pure capital aggregator and scientific gatekeeper — a lean structure that distinguishes it from vertically integrated research charities. Team information and total assets under management are not publicly disclosed, consistent with many small-to-mid-sized disease foundations that file limited IRS Form 990 detail. The institute's professional footprint is likely modest, relying on a network of volunteer scientific reviewers and a small executive staff to manage grant administration, donor relations, and research portfolio oversight. It maintains no additional domestic or international offices. Philanthropic giving appears to originate from patient families and private donors affected by follicular lymphoma, though no specific wealth-origin attribution or named principal donors are on the public record. Structurally, the institute operates as a focused grantmaking common fund rather than a multi-program foundation or a direct research enterprise. This architecture allows it to pivot funding priorities rapidly as the science evolves — an advantage over larger, bureaucratic cancer charities. Its succession and governance model remains opaque, but the absence of a named billionaire founder or family-office backing suggests a distributed donor base and board-driven oversight. That governance distinction shapes its risk tolerance: it can fund the science that academic labs and biotech startups require to bridge the valley of death between target identification and Series A financing.
General information
Firm type
Foundation
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Diamond Bar
Corporate office
Diamond Bar, CA, United States
Sector focus
Frequently asked questions
What is the Institute for Follicular Lymphoma Innovation's primary funding model?
The institute operates as a pure grantmaking foundation, aggregating philanthropic donations and channeling them to academic and clinical researchers through a competitive, science-advisory-board-reviewed annual grant cycle. It does not run its own labs, clinics, or commercial ventures, keeping overhead low to maximize direct research capital deployment. The model is built to fund investigator-initiated translational projects that are too early or too niche for large pharmaceutical R&D budgets.
Which research areas and mechanisms does the institute prioritize?
Grantmaking focuses on novel therapeutic strategies for follicular lymphoma, including bispecific antibody platforms, next-generation CAR-T constructs, and epigenetic modulators. The institute explicitly targets high-risk projects in biomarker discovery and early-stage translational science that aim to move the disease from a relapsing chronic condition toward durable remission or cure. Portfolio emphasis has historically centered on immunotherapeutic approaches, reflecting the scientific advisory board's view of the highest-leverage investment in the current treatment landscape.
Where does the institute's funding geographically concentrate?
Awards are distributed across major academic medical centers in the United States and Europe. Named grantee institutions in the public record include MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. The institute does not maintain any clinical sites or international satellite offices, operating solely from its Diamond Bar, California administrative headquarters.
How does this foundation differ from larger cancer charities?
The institute concentrates its entire capital allocation on a single disease — follicular lymphoma — rather than spreading funding across multiple cancer types or general awareness campaigns. Its lean governance structure and narrow scientific focus allow it to respond quickly to emerging research opportunities and fund projects that would be deprioritized by broader foundations or commercial drug developers. The model trades diversified donor appeal for deep, specialist-led scientific decision-making.
Who governs the research funding decisions?
Grant awards are guided by a scientific advisory board composed of lymphoma specialists and translational researchers, though the named composition of this board is not consistently published. The board reviews applications, prioritizes projects based on scientific merit and potential patient impact, and oversees the active grant portfolio. The board's specialist composition is the key quality signal for the foundation — funding decisions are made by peers of the applying researchers, not generalist program officers.
Is any wealth-origin or family-office backing publicly attributed?
No single named donor, founding family, or family-office affiliation appears in the public record for this institute. Available information points toward a distributed donor base of patient families and private contributors affected by follicular lymphoma. The absence of a disclosed billionaire founder or institutional anchor suggests a community-funded, board-driven governance model rather than a single-family philanthropic vehicle.
Does the institute take equity positions in biotech startups or commercialize research?
The institute functions solely as a charitable grantmaker and does not operate a venture-philanthropy model that would involve taking equity in funded spinouts. It funds academic-stage translational science without commercial strings — the research it supports is intended to generate data and proofs-of-concept that can attract follow-on funding from venture capital, biotech, or pharmaceutical partners. This pure grant posture distinguishes it from impact-first models that blur charitable and for-profit returns.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: